FINWIRES · TerminalLIVE
FINWIRES

PhillipCapital Adjusts Singapore Airlines' Price Target to SG$6.43 from SG$7, Keeps at Neutral

By

Singapore Airlines (SGX:C6L) has an average rating of hold and mean price target of SG$6.49, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Asia

CCI Group Declares Lower Year-End Dividend for Fiscal 2025

CCI Group (TYO:7381) declared a year-end dividend of 12 yen per share for fiscal 2025 ended March 31, lower than the 60 yen per share paid a year ago on a post-split basis.The total dividend payment amounts to 2.69 billion yen, payable from retained earnings on June 1, according to a Tokyo bourse filing on Friday.For fiscal 2026, CCI Group expects a total dividend of 23 yen per share, post-split basis, consisting of an interim dividend of 11 yen and a year-end dividend of 12 yen.

$TYO:7381
Asia

Nippon Concrete Industries to Absorb Wholly-Owned Subsidiary, Eyes Extraordinary Loss

Nippon Concrete Industries (TYO:5269) has approved an absorption-type merger of its wholly-owned subsidiary, NC Management Service (NCMS), effective Oct. 1, according to a Tokyo bourse filing on Friday.The merger aims to improve group management efficiency and consolidate operations, as NCMS manages land and buildings used by manufacturing subsidiaries within the group.Since NCMS is a wholly-owned subsidiary, the merger will be carried out under simplified procedures without requiring a shareholder vote at the subsidiary level.The company expects to record a loss on extinguishment of tie-in shares as an extraordinary loss in its non-consolidated financial results, though the exact amount has not yet been determined.

$TYO:5269
Asia

CSPC Innovation Pharma Gets China Nod for Psoriasis Drug

CSPC Innovation Pharmaceutical (SHE:300765, HKG:1093) received drug registration from China's medical products administrator for ustekinumab injection.The drug, branded as Enyike, is used to treat moderate to severe plaque psoriasis, according to Friday filings with the Shenzhen and Hong Kong bourses.

$HKG:1093$SHE:300765